Tipelukast (KCA 757 or MN-001) is a sulfidopeptide
leukotriene receptor antagonist with suspected anti-inflammatory properties. It is developed by MediciniNova.[1][2][3][4]
^Bascom, R.; Hitz, K.; Dimmock, A.E.F.; Makhay, M.; Dojillo, J.; Matsuda, K. (May 2020). "Description of Protocol to Evaluate MN-001'S (tipelukast) Efficacy, Safety and Tolerability in Subjects with Idiopathic Pulmonary Fibrosis". A37. Ild Therapy I. pp. A1493.
doi:
10.1164/ajrccm-conference.2020.201.1_MeetingAbstracts.A1493.
S2CID225921518.